Articles from The Fly (June 14, 2024)

1-58 out of 58 article(s)

Title	Type	Words
AbbVie recommends shareholders reject Tutanota's 'mini-tender' offer.		226
Actinium Pharmaceuticals presents results of Phase 3 SIERRA trial of Iomab-B.		185
Action Economics Weekly Survey results.		187
Advance Auto Parts reports cyber security incident.		192
After Kyverna data, Oppenheimer says Cartesian 'can exploit' CAR-T's 'baggage'.		163
Ainos announces progress in clinical trials of Ainos Flora.		270
American Resources responds to market volatility, posts of false information.		432
Ameriserve Financial enters cooperation, settlement agreement with Driver.		205
Amgen says FDA approves BLINCYTO.		222
Aptose Biosciences announces poster presentation, e-poster at EHA.		215
Aslan Pharmaceuticals plans to implement ADS ratio change.		188
Autolus Therapeutics to present three clinical data updates on obe-cel.		501
Avinger prices 3.61M shares at $1.66 in public offering.		357
Beam Therapeutics reports data from BEAM-101 trial.		235
BeiGene to present new data from SEQUOIA study of BRUKINSA.		240
Bernstein sees bitcoin hitting $200,000 next year, bullish on MicroStrategy.		221
Bio-Path presents data from ongoing Phase 2 combination study of prexigebersen.	Clinical report	266
Cabaletta Bio reports clinical data from first two patients dosed with CABA-201.		609
Cogent Biosciences announces clinical data from Part 1 of ongoing SUMMIT trial.		260
Disc Medicine presents clinical data across portfolio at EHA 2024 Congress.	Clinical report	622
Editas Medicine announces new safety, efficacy data from EdiTHAL trial.		338
Editas Medicine announces new safety, efficacy data from RUBY trial.		395
Elevai Labs forms Scientific Advisory Board for weight loss programs.		188
enGene reports Q2 EPS (38c), consensus (26c).	Financial report	168
Fedspeak will be closely monitored.		183
Fluor team awarded NNSA's Pantex plant management and operating contract.		209
Forward Industries announces 1-for-10 reverse stock split.		194
Foxo Technologies receives noncompliance notice from NYSE.		173
Galapagos presents new data from ATALANTA-1 study.		484
Gilead announces results from three new analyses for Yescarta at EHA.	Financial report	396
Hurco Companies announces suspension of quarterly cash dividend.		177
Jasper Therapeutics presents data from preclinical briquilimab study.		207
Johnson & Johnson reports long-term data from Phase 1/2 MonumenTAL-1 study.		166
JPMorgan upgrades Adobe to Overweight on 'smoother sailing ahead'.		154
Kymera Therapeutics presents clinical data from Phase 1 trial of KT-333.		517
Market Action: Treasuries are holding gains.		206
Market Update: Treasuries in the green.		154
Market Update:.		237
Market Update:.		157
Molecular Partners announces preclinical data from MP0621 trial.		235
Moleculin Biotech reports data from Phase 1B/2 (MB-106) clinical trial.		358
Musk pay package approval 'relief' for Tesla holders, says Bernstein.		160
Novavax submits application to FDA for updated COVID-19 vaccine formula.		163
Nucor sees Q2 EPS $2.20-$2.30, consensus $2.99.	Financial report	169
Penn falls after Truist says strategic review not likely near-term.		151
Pfizer announces overall survival data from MagnetisMM-3 study of Elrexfio.	Clinical report	554
Renalytix announces Medicare issued coverage determination for kidneyintelX.dkd.		153
Resideo sees Snap One acquisition as accretive to FY25 non-GAAP adjusted EPS.		223
Samsung showcases AI-era vision, latest technologies at SFF 2024.		217
Shattuck Labs reports 'positive' interim data from Phase 1B trial of SL-172154.		329
Syndax reports new data from AUGMENT-102 trial.		342
Syndax reports new data from BEAT AML trial of revumenib/venetoclax/azacitidine.		381
Takeda enters exclusive license agreement for olverembatinib with Ascentage.		213
The preliminary Michigan sentiment report.		182
The U.S. trade price report.		197
Treasury Market Summary:.		225
Vertex Pharmaceuticals presents long-term Casgevy trial data.		376
Zura Bio presents data for tibulizumab program at EULAR 2024.		294